Nilutamide

CHEMBL1274 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

317.2 g/mol

LogP

2.0

Phase

4

An anti-androgen medication that blocks the effects of male hormones that stimulate the growth of prostate cancer cells.

Peso Molecular

317,2200 g/mol

LogP

2,00

TPSA

95,20 Å²

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Prostate Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O

InChI

InChI=1S/C12H10F3N3O4/c1-11(2)9(19)17(10(20)16-11)6-3-4-8(18(21)22)7(5-6)12(13,14)15/h3-5H,1-2H3,(H,16,20)

Molecular Formula

C12H10F3N3O4

HBD / HBA

1 / 7

Ligações Rotacionáveis

1

Átomos Pesados

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An anti-androgen medication that blocks the effects of male hormones that stimulate the growth of prostate cancer cells.

Yes, Nilutamide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1274. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 4493. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Procura informações acessíveis para o paciente?

Nilutamide no PillFYI

Estrutura

Dados Rápidos

Fórmula: C12H10F3N3O4
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.